002099.SZ
002099.SZ
CNE000001PY2
HISOAR
Loading chart...

Company Profile

Zhejiang Hisoar Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in China and internationally. It operates through Pharmaceutical Industry, Dye Industry, and Others segments. The company offers antibiotics, cardiovascular drugs, hypoglycemic agents, formulations, and fine chemicals. It also provides dyes and pigment intermediates; environmental protection-related equipment; medical chemical supplies and appliances; and other chemical intermediates. In addition, the company engages in technology research and development; trading; hazardous waste treatment; equity investment; technical consulting and other consulting services; and venture capital activities. It exports its products to approximately 30 countries, including Europe, America, and Asia. Zhejiang Hisoar Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Taizhou, China.

Related stocks

600812.SS
600812.SS • China
NORTH CHINA PHARMACEUTICAL CO
6.03 CNY
1.55B USD 1Y +1.5%
600993.SS
600993.SS • China
MAYINGLONG PHARMACEUTICAL GP CO
22.95 CNY
1.48B USD 1Y -15%
600572.SS
600572.SS • China
ZHEJIANG CONBA PHARMACEUTICAL C
4.41 CNY
1.68B USD 1Y +0.5%
600216.SS
600216.SS • China
ZHEJIANG MEDICINE
12.59 CNY
1.81B USD 1Y -12.9%
1681.HK
1681.HK • China
CONSUN PHARMA
14.85 HKD
1.59B USD 1Y -13.6%
301263.SZ
301263.SZ • China
TEK
19.14 CNY
1.22B USD 1Y -31.8%
600211.SS
600211.SS • China
TIBET RHODIOLA PHARMACEUTICAL H
36.78 CNY
1.77B USD 1Y -22.9%
600789.SS
600789.SS • China
SHANDONG LUKANG PHARMACEUTICAL
8.28 CNY
1.29B USD 1Y -15.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
40.1% p.a.
Max Drawdown (5Y)
-57.4%
Sharpe Ratio (5Y)
-0.17
Beta Factor
0.30
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Elevated Short-Term Volatility: 3Y volatility (45.0%) is noticeably higher than the 5Y average (40.1%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -63.6% in the extended horizon.
ende